NCT05070403进行中（未招募）2 期
Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Overall Response Rate
研究概览
简要总结
The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years at the time of informed consent
- •ECOG performance status ≤2
- •Adequate bone marrow, organ function and laboratory parameters:
- •ANC ≥ 1.0 × 109/L;
- •Hemoglobin ≥ 8 g/dL;
- •Platelets ≥ 75 × 109/L;
- •AST and ALT ≤5 × ULN
- •Calculated creatinine clearance > 15mL/min by Cockroft-Gault formula
- •Histologic diagnosis of invasive cutaneous squamous cell carcinoma, that is deemed not appropriate for further surgical intervention and/or radiation therapy. Participants may have either locally advanced or metastatic disease.
- •At least 1 measurable lesion - either per RECIST 1.1 criteria, or for patients with externally visible cuSCC lesion(s) not measurable on imaging, at least one lesion ≥1 cm in longer diameter, amenable to digital photography with bi-dimensional measurements
- •Participants must have received prior immunotherapy with an anti-PD-1/PD-L1 antibody, if participant was deemed eligible (i.e., was not immunosuppressed or a transplant receipt, etc)
- •Immunosuppressed participant including those with concurrent autoimmune diseases and solid organ transplant recipients are eligible
- •Prior to first dose of study treatment, participant must be at least 2 weeks from any prior systemic therapy, major surgery or radiation
- •Able to undergo a pre-treatment and on-treatment tumor biopsy
- •Female participants of childbearing potential must have a negative serum or urine β-HCG test result. Female participants of childbearing potential and male participants must agree to use methods of contraception that are highly effective.
- •Participants with brain metastases are permitted assuming that the brain metastases have been adequately treated with prior surgery or radiation.
排除标准
- •In participants with known liver cirrhosis, those with severe (Child Pugh C) hepatic impairment will be excluded.
- •Untreated, uncontrolled or symptomatic brain metastases or leptomeningeal carcinomatosis that are not stable or require corticosteroids,
- •Participants with mixed histologies (eg, sarcomatoid, adenosquamous) will generally not be eligible, unless the predominant histology is invasive cuSCC.
- •Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- •Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 90 days prior to randomization. Participants with a known history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with HCV infection who are currently on treatment must have an undetectable HCV viral load prior to randomization.
- •Pregnancy or breast feeding.
研究组 & 干预措施
Afatinib Intervention
Experimental
Participants will receive afatinib 40 mg once a day. Each cycle is 4 weeks. They will have CT imaging (and/or digital photography) done at baseline and every 8 weeks while on treatment. Participants will have a baseline and on-treatment (at 4 weeks) tumor biopsy, and a biopsy at disease progression if feasible. Patients may remain on treatment as long as they are deriving clinical benefit, until disease progression or intolerable toxicity.
干预措施: Afatinib 40 MG (Drug)
结局指标
主要结局
Overall Response Rate
时间窗: Up to 1 Year
Overall response rate (ORR) as defined by proportion of patients who have achieved a complete or partial response per RECIST 1.1 criteria
次要结局
- Progression free survival(Up to 5 Years)
- Overall survival(Up to 5 Years)
- Treatment-related adverse events(Up to 40 days after end of treatment)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLCAdvanced Squamous Non Small Cell Lung CancerNCT04497584University of Texas Southwestern Medical Center12
Unknown
2 期
Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)Esophageal Squamous Cell CarcinomaNCT03940976Peking University40
招募中
1 期
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaEsophagus CancerNCT06753747West China Hospital45
Unknown
2 期
Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical ResectionCarcinoma, HepatocellularNCT03261791Shanghai Zhongshan Hospital30
Unknown
2 期
Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract CancersBiliary Tract CancerNCT03144856Sun Yat-sen University39